InvestorsHub Logo
Followers 87
Posts 6642
Boards Moderated 1
Alias Born 09/18/2009

Re: None

Tuesday, 11/28/2023 6:28:46 AM

Tuesday, November 28, 2023 6:28:46 AM

Post# of 42751
"Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization...

NEWS PROVIDED BY

NOVAVAX, INC
28 Nov, 2023, 06:00 ET

The EUL was based on non-clinical data showing that Novavax's COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax's vaccine induced neutralizing antibody responses to subvariants BA.2.86, EG.5.1, FL.1.5.1 and XBB.1.16.6 as well as CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax's vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants.5,6

In clinical trials, the most common adverse reactions associated with Novavax's prototype COVID-19 vaccine (NVX-CoV2373) included headache, nausea or vomiting, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue and malaise."

https://www.prnewswire.com/news-releases/novavaxs-updated-protein-based-covid-19-vaccine-now-an-option-for-all-194-member-states-of-the-world-health-organization-301998533.html

Again, I hope the prototype clinical trials are evaluating the use of the lenz cocktail.